ATE360077T1 - 22025, eine neue menschliche zyklische nukleotiden phosphodiesterase - Google Patents
22025, eine neue menschliche zyklische nukleotiden phosphodiesteraseInfo
- Publication number
- ATE360077T1 ATE360077T1 AT00941369T AT00941369T ATE360077T1 AT E360077 T1 ATE360077 T1 AT E360077T1 AT 00941369 T AT00941369 T AT 00941369T AT 00941369 T AT00941369 T AT 00941369T AT E360077 T1 ATE360077 T1 AT E360077T1
- Authority
- AT
- Austria
- Prior art keywords
- phosphodiesterase
- polynucleotides
- invention further
- cyclic nucleotide
- polypeptides
- Prior art date
Links
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 title abstract 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 7
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 7
- 239000002157 polynucleotide Substances 0.000 abstract 5
- 102000040430 polynucleotide Human genes 0.000 abstract 5
- 108091033319 polynucleotide Proteins 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 239000000556 agonist Substances 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 238000007877 drug screening Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04017—3',5'-Cyclic-nucleotide phosphodiesterase (3.1.4.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/330,970 US6146876A (en) | 1999-06-11 | 1999-06-11 | 22025, a novel human cyclic nucleotide phosphodiesterase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE360077T1 true ATE360077T1 (de) | 2007-05-15 |
Family
ID=23292085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00941369T ATE360077T1 (de) | 1999-06-11 | 2000-06-12 | 22025, eine neue menschliche zyklische nukleotiden phosphodiesterase |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6146876A (de) |
| EP (1) | EP1192261B1 (de) |
| JP (1) | JP2003502046A (de) |
| AT (1) | ATE360077T1 (de) |
| AU (1) | AU5608000A (de) |
| DE (1) | DE60034450T2 (de) |
| ES (1) | ES2284502T3 (de) |
| WO (1) | WO2000077226A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1018559T3 (da) | 1998-12-23 | 2007-12-03 | Pfizer | Phosphodiesteraser |
| GB9930058D0 (en) * | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
| CA2400606A1 (en) * | 2000-02-21 | 2001-08-30 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | New phosphodiesterase type 7b |
| US6500628B1 (en) * | 2000-05-25 | 2002-12-31 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding human kinase and phosphatase homologues and uses therefor |
| US20040054138A1 (en) * | 2001-06-21 | 2004-03-18 | Thornton Michael B. | Phosphodiesterases |
| WO2001098471A2 (en) * | 2000-06-22 | 2001-12-27 | Incyte Genomics, Inc. | Human phosphodiesterases |
| US20030054531A1 (en) * | 2001-03-19 | 2003-03-20 | Decode Genetics Ehf, | Human stroke gene |
| DE60237696D1 (de) * | 2001-08-01 | 2010-10-28 | Univ Utah | Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a |
| US20050164275A1 (en) * | 2002-10-18 | 2005-07-28 | Incyte Corporation | Phosphodiesterases |
| WO2004044196A1 (en) * | 2002-11-13 | 2004-05-27 | Bayer Healthcare Ag | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7B (PDE7b) |
| WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
| EP2377530A3 (de) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation von Neurogenese durch PDE-Hemmung |
| EP1942879A1 (de) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
| EP2021000A2 (de) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenese mittels angiotensin-modulation |
| BRPI0716604A2 (pt) * | 2006-09-08 | 2013-04-09 | Braincells Inc | combinaÇÕes contendo um derivado de 4-acilaminopiridina |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| RU2449790C2 (ru) | 2007-03-27 | 2012-05-10 | Омерос Корпорейшен | Использование ингибиторов pde7 для лечения нарушений движения |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN107375296A (zh) | 2010-11-08 | 2017-11-24 | 奥默罗斯公司 | 使用pde7抑制剂治疗成瘾和冲动控制障碍 |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080540A (en) * | 1990-04-20 | 2000-06-27 | Cold Spring Harbor Laboratory | Cloning of mammalian genes in microbial organisms and methods for pharmacological screening |
| PT652960E (pt) * | 1993-05-27 | 2001-08-30 | Icos Corp | Materiais para fosfodiesterases especificas e de ligacao do mpg ciclico e respectivos metodos |
| CA2182946A1 (en) * | 1994-12-23 | 1996-07-04 | Raymond John Owens | Human phosphodiesterase type ivc, and its production and use |
| US5798246A (en) * | 1996-03-25 | 1998-08-25 | Incyte Pharmaceuticals, Inc. | Cyclic nucleotide phosphodiesterase |
| DK1018559T3 (da) * | 1998-12-23 | 2007-12-03 | Pfizer | Phosphodiesteraser |
| JP3648109B2 (ja) * | 1998-12-23 | 2005-05-18 | ファイザー・インク | ホスホジエステラーゼ酵素 |
-
1999
- 1999-06-11 US US09/330,970 patent/US6146876A/en not_active Expired - Fee Related
-
2000
- 2000-06-12 AU AU56080/00A patent/AU5608000A/en not_active Abandoned
- 2000-06-12 JP JP2001503668A patent/JP2003502046A/ja active Pending
- 2000-06-12 AT AT00941369T patent/ATE360077T1/de not_active IP Right Cessation
- 2000-06-12 WO PCT/US2000/016116 patent/WO2000077226A1/en not_active Ceased
- 2000-06-12 ES ES00941369T patent/ES2284502T3/es not_active Expired - Lifetime
- 2000-06-12 EP EP00941369A patent/EP1192261B1/de not_active Expired - Lifetime
- 2000-06-12 DE DE60034450T patent/DE60034450T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1192261A1 (de) | 2002-04-03 |
| DE60034450D1 (de) | 2007-05-31 |
| DE60034450T2 (de) | 2008-01-03 |
| JP2003502046A (ja) | 2003-01-21 |
| ES2284502T3 (es) | 2007-11-16 |
| EP1192261B1 (de) | 2007-04-18 |
| WO2000077226A1 (en) | 2000-12-21 |
| US6146876A (en) | 2000-11-14 |
| AU5608000A (en) | 2001-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60034450D1 (de) | 22025, eine neue menschliche zyklische nukleotiden phosphodiesterase | |
| WO2001057081A3 (en) | Narc-1, subtilase-like homologs | |
| WO2001032891A3 (en) | Human lipase | |
| EP0849361A3 (de) | Neue Liganden des Neuropeptide Rezeptors HFGAN72 | |
| DE60213629D1 (de) | Piperidinverbindungen als muscarinantagonisten | |
| ATE373718T1 (de) | 17867, eine menschliche aminopeptidase | |
| MXPA03005436A (es) | Polinucleotidos novedosos que codifican fosfastasas humanas. | |
| WO2003002604A3 (en) | G protein coupled receptors and dna sequences thereof | |
| WO2003048323A3 (en) | Polynucleotides and polypeptides associated with the development of rheumatoid arthritis | |
| WO2004039940A3 (en) | Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof | |
| WO2001064880A3 (en) | Human dynamin 40322 | |
| WO2001036605A3 (en) | 2786, a human aminopeptidase | |
| WO2001023589A3 (en) | 23431, a novel human ubiquitin protease | |
| WO2001023590A3 (en) | 22196, a novel human aminopeptidase | |
| WO2003027231A3 (en) | Polynucleotide encoding adapter protein, pmn29 | |
| ATE348889T1 (de) | 27411, eine menschliche phosphatidyl- glycerinphosphate (pgp) synthase | |
| WO1999030670A3 (en) | Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof | |
| WO2002030979A3 (en) | Polypeptides homologous to thymosin, ephrin a receptors, and fibromodulin, and polynucleotides encoding same | |
| WO2001044446A3 (en) | Further human alcohol dehydrogenases | |
| WO2001000812A3 (en) | 22012, a novel human carboxypeptidase | |
| WO2001059081A3 (en) | Methods for using 20893, a human protein kinase | |
| IL155687A0 (en) | Polynucleotides encoding hlrrsi1 polypeptides | |
| WO2001032885A3 (en) | Human lipase | |
| WO2001064873A3 (en) | Human gtpase activator proteins | |
| WO2001062940A3 (en) | New phosphodiesterase type 7b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |